0.8476  -0.014 (-1.58%)		01-14 11:18
Open: 0.87 High: 0.8849 Volume: 162,866		Pre. Close: 0.8612 Low: 0.8402 Market Cap: 96(M)

Short term
Mid term
Targets	6-month :	1.16	1-year :	1.31
Resists	First :	0.99	Second :	1.12
Pivot price	0.85
Supports	First :	0.77	Second :	0.64
MAs	MA(5) :	0.87	MA(20) :	0.87
	MA(100) :	1.31	MA(250) :	1.52
MACD	MACD :	-0.1	Signal :	-0.1
%K %D	K(14,3) :	51.3	D(3) :	52.1
RSI	RSI(14): 37
52-week	High :	2.95	Low :	0.77

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ ARAY ] has closed above bottom band by 44.0%. Bollinger Bands are 64.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 4 bars. This is a sign that the market may be about to initiate a new trend.

If tomorrow:	Open lower	Open higher
High:	0.88 - 0.89	0.89 - 0.89
Low:	0.84 - 0.85	0.85 - 0.85
Close:	0.85 - 0.86	0.86 - 0.87

Accuray Incorporated designs, develops, manufactures, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the United States, Canada, Latin America, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, China, and rest of the Asia Pacific region. It offers the CyberKnife System, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate. The company also provides the TomoTherapy System, including the Radixact System, which allows for integrated radiation treatment planning, delivery, and data management, enabling clinicians to deliver ultra-precise treatments to approximately 50 patients per day; iDMS data management system, a fully integrated treatment planning and data management systems; and Accuray precision treatment planning system, a treatment planning and data management systems. In addition, it offers post-contract customer support, installation, training, and other professional services. The company primarily markets its products directly to customers, including hospitals and stand-alone treatment facilities through its sales organization, as well as to customers through sales agents and group purchasing organizations in the United States; and to customers directly and through distributors and sales agents internationally. Accuray Incorporated was incorporated in 1990 and is headquartered in Madison, Wisconsin.

Sun, 11 Jan 2026
The past five years for Accuray (NASDAQ:ARAY) investors has not been profitable - Yahoo Finance

Wed, 07 Jan 2026
Following a 59% decline over last year, recent gains may please Accuray Incorporated (NASDAQ:ARAY) institutional owners - simplywall.st

Wed, 07 Jan 2026
Following a 59% decline over last year, recent gains may please Accuray Incorporated (NASDAQ:ARAY) institutional owners - Sahm

Mon, 15 Dec 2025
Accuray announces first phase of comprehensive strategic, operational, and organizational transformation plan; company expects first phase to improve annualized operating profitability by approximately $25 million and set the stage for renewed growth - PR Newswire

Tue, 02 Dec 2025
Little Excitement Around Accuray Incorporated's (NASDAQ:ARAY) Revenues As Shares Take 28% Pounding - simplywall.st

Fri, 07 Nov 2025
Accuray Inc (ARAY) Q1 2026 Earnings Call Highlights: Navigating Challenges with Strategic ... - Yahoo Finance

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Underperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Medical - Devices
Shares Out	113 (M)
Shares Float	108 (M)
Held by Insiders	4 (%)
Held by Institutions	69.6 (%)
Shares Short	3,880 (K)
Shares Short P.Month	3,240 (K)

EPS	-0.16
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0.55
Profit Margin	-4.3 %
Operating Margin	3.7 %
Return on Assets (ttm)	0.2 %
Return on Equity (ttm)	-36.1 %
Qtrly Rev. Growth	16.7 %
Gross Profit (p.s.)	1.23
Sales Per Share	3.97
EBITDA (p.s.)	0.06
Qtrly Earnings Growth	0 %
Operating Cash Flow	22 (M)
Levered Free Cash Flow	21 (M)

PE Ratio	-5.31
PEG Ratio	0
Price to Book value	1.54
Price to Sales	0.21
Price to Cash Flow	4.3

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.